Asthma Disease Management Gets 15 Million Financing 322000

NJBIZ STAFF//August 9, 2005//

Listen to this article

Asthma Disease Management (OTC BB: ADMI) of Berlin yesterday said Securities Capital Trading has agreed to invest $15 million in the company in return for an equity interest.

ADMI will use a portion of the proceeds for the acquisition of one of the seven remaining FDA approved allergen manufacturing laboratories in America and also to bring to market a new treatment, which holds promise of permanent relief for people suffering from asthma and allergic diseases. Additionally, ADMI will use the money to support the expansion of its operations. ADMI plans to enter the field of veterinary medicine with a treatment program for canines.

The company develops and markets proprietary asthma disease management programs. The programs combine physician training, testing for asthma triggers and other allergic diseases, vaccinations, home health visits, demand management, and case management.